论文部分内容阅读
多发性骨髓瘤(MM)是浆细胞恶性克隆增殖性疾病,约占恶性肿瘤的1%,血液系统肿瘤的10%～15%,多见于中老年人,在欧美国家中位发病年龄约65岁(范围50～70岁),而国内报道中位发病年龄为58岁〔1〕。传统化疗完全缓解(CR)率一般小于10%,中位生存期30～36个月,其他更
Multiple myeloma (MM) is a proliferative disease of plasma cell malignant clone, accounting for about 1% of malignant tumors and 10% -15% of hematological malignancies. It is more common in middle-aged and elderly people and has a median age of onset of about 65 years in European and American countries (Range 50 to 70 years old), while the median reported incidence of 58 years old [1]. Traditional chemotherapy complete remission (CR) rate is generally less than 10%, the median survival of 30 to 36 months, the other more